Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1941-1950 of 2762 for

Edit search filters
  1. A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

    Scottsdale/Phoenix, AZ

  2. LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

  3. Phase 2 Nab®-Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects with Locally Advanced Pancreatic Cancer (LAPC)

    Scottsdale/Phoenix, AZ

  4. Modafinil in Treating Children with Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

    Rochester, MN

  5. A Study Using Chemotherapy Followed by Radiation Therapy in Treating Younger Patients with Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

    Rochester, MN

  6. A Study of Using Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

    Rochester, MN

  7. Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. A Study of Niraparib Combined with Pembrolizumab (MK-3475) in Patients who have Triple-Negative Breast Cancer or Ovarian Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  9. A Study of Shared Decision Making with Patients who have Thyroid Nodules

    Rochester, MN

  10. A Study of Cediranib and Olaparib Combined, Compared to Either Drug Alone, or to a Standard Chemotherapy in Treating Patients who have a Return of Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    La Crosse, WI, Rochester, MN, Mankato, MN

.

Mayo Clinic Footer